Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing agreement with fellow Chinese firm Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), securing exclusive commercialization rights for Sihuan’s Category 1 drug, janagliflozin, in mainland China. Under the terms of the agreement, Huadong will handle the market promotion of the drug, while Sihuan will oversee regulatory filings, clinical development, manufacturing, and supply. Financial details of the deal were not disclosed.
Janagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, offers protective effects on the cardiovascular system and kidneys, in addition to effectively managing blood sugar levels. The drug is under patent protection in several regions, including mainland China, the US, Europe, Japan, South Korea, and Hong Kong. It received approval in China in January of this year for the control of blood sugar levels in adults with type 2 diabetes, either as a standalone therapy or in combination with metformin.- Flcube.com
